Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMK 389

Next Previous
Search
Drug Profile

CMK 389

Alternative Names: CMK-389; NOV-8

Latest Information Update: 25 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Anti-inflammatories; Antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Pulmonary sarcoidosis

Most Recent Events

  • 12 Dec 2023 Novartis Pharmaceuticals completes the phase II trial in Pulmonary sarcoidosis in USA, Poland, Czech Republic, Denmark, United Kingdom, Germany (IV) (NCT04064242)
  • 13 Dec 2022 Novartis Pharmaceuticals completes a phase II trial in Atopic dermatitis in Czech Republic, France, Germany, Hungary, Poland, Spain (IV) (SC) (EudraCT2020-003406-31) (NCT04836858)
  • 20 Apr 2021 Phase-II clinical trials in Atopic dermatitis in Spain, Poland, Germany, France, Czech Republic, Hungary (SC) (EudraCT2020-003406-31) (NCT04836858)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top